Guggenheim analyst Subbu Nambi lowered the firm’s price target on Exact Sciences (EXAS) to $60 from $73 and keeps a Buy rating on the shares.

Exact Sciences Corporation’s EXAS investment in high-return pipeline opportunities with significant patient impacts should drive growth in the upcoming quarter. Additionally, the company is advancing ...

A month has gone by since the last earnings report for Exact Sciences (EXAS). Shares have lost about 10.6% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

The dog signs off on a distinctly potty-mouthed note: “So, come on: Pick up your s*** and let’s f*** colon cancer,” it says ...

Learn more about whether Exact Sciences Corporation or Kymera Therapeutics, Inc. is a better investment based on AAII's A+ ...

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to ...

RBC Capital initiated coverage of Exact Sciences (EXAS) with a Sector Perform rating and $52 price target while launching coverage of the ...

EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Exact Sciences Corporation’s EXAS investment in high-return pipeline opportunities with significant patient impacts should drive growth in the upcoming quarter. Additionally, the company is ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...